Polish gynaecological society guidelines for Human Papilloma Virus (HPV) vaccination;Rekomendacje zespu ekspertów polskiego towarzystwa ginekologicznego. Dotyczàce szczepienia przeciwko zakãeniom HPV

Ginekologia Polska

Volumn 80, Issue 2, 2009, Pages 139-146

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ARTICLE; FEMALE; HEALTH CARE QUALITY; HUMAN; IN SERVICE TRAINING; MEDICAL SOCIETY; ORGANIZATION; ORGANIZATION AND MANAGEMENT; POLAND; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PRIMARY PREVENTION; PUBLIC HEALTH; STANDARD; VACCINATION; VIRUS INFECTION;

CONGRESSES AS TOPIC; FEMALE; HUMANS; INSERVICE TRAINING; NATIONAL HEALTH PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; POLAND; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRIMARY PREVENTION; QUALITY ASSURANCE, HEALTH CARE; SOCIETIES, MEDICAL; VACCINATION;

EID: 65349168845     PISSN: 00170011     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (10)

1. American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors. CA Cancer J Clin. 2007, 57, 7-28. http://caonline.amcancersoc.org/cgi/content/full/57/1/7
2. Bosch X, Stanley M, Harper D, [et al.]. HPV Master Class. Ustne doniesienia na Konferencji HPV, Madryt:2007.
3. Dane rejestracyjne szczepionek w Europejskiej Komisji ds. Leków: www.emea.europa.eu
4. Dane z bazy NCI: www.cancer.gov
5. Charakterystyka Produktu Leczniczego szczepionki SILGARD
6. Brown D. (Grupa badawcza FUTURE). HPV Type 6/11/16/18 Vaccine: First Analysis Of Cross-Protection Against Persistent Infection, Cervical Intraepithelial Neoplasia (CIN), And Adenocarcinoma In Situ (AIS) Caused By Oncogenic HPV Types In Addition To 16/18. prezentacja G-1720b. Kongres ICAC, Waszyngton: 17-20 wrzeÊnia 2007. Dost́pne 13.11.2008 r. http://www.ginec.org/descargas/ICAAC2007_XPposterBROWN_final_edumec_27_s et. pdf
7. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 ASO4adjuvanted cervical cancer vaccine: importance of virology and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol. 2008, 110, (3 Suppl 1), 18-25.
8. Luna J, [et al.]. Safety, Efficacy, and Immunogenicity of quadrivalent HPV vaccine (Gardasil) in women aged 24-45. (Presentation #PA1-04). 24th International Papillomavirus Congress. 3-9 listopada 2007. Chiny. Dostepne: 13.11.2008 r. http://ipv.meeting.orthonline.com.cn/user/en_user_login.asp Badanie FUTURE III
9. Olsson S-E, Villa L, Costa R, [et al.]. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007, 25, 4931-4939.
10. Program Szczepień Ochronnych na rok 2008